{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:20:10Z","timestamp":1778556010305,"version":"3.51.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.beha.2020.101195","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T01:29:37Z","timestamp":1593912577000},"page":"101195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Molecular genetics of MDS\/MPN overlap syndromes"],"prefix":"10.1016","volume":"33","author":[{"given":"Anthony M.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2020.101195_bib1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2020.101195_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2020.101195_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.beha.2020.101195_bib5","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2010-07-295857","article-title":"Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies","volume":"117","author":"Tiu","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101195_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2020.101195_bib7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101195_bib8","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Canc J"},{"issue":"15","key":"10.1016\/j.beha.2020.101195_bib9","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101195_bib10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cam4.1946","article-title":"Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia","volume":"8","author":"Faisal","year":"2019","journal-title":"Canc Med"},{"issue":"19","key":"10.1016\/j.beha.2020.101195_bib11","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2020.101195_bib12","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2020.101195_bib13","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2020.101195_bib14","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Canc Res"},{"issue":"4","key":"10.1016\/j.beha.2020.101195_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2020.101195_bib16","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101195_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ajh.24939","article-title":"Therapy related-chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2020.101195_bib18","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions","volume":"104","author":"Valent","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib19","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","article-title":"Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol"},{"issue":"22","key":"10.1016\/j.beha.2020.101195_bib20","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood.V128.22.4337.4337","article-title":"SRSF2 mutations identify a distinct subtype of myeloid neoplasm across myelodysplastic syndromes and acute myeloid leukemia","volume":"128","author":"Todisco","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2020.101195_bib22","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2020.101195_bib23","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2020.101195_bib24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V77.5.925.925","article-title":"Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors","volume":"77","author":"Emanuel","year":"1991","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2020.101195_bib25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/ped.13068","article-title":"Diagnosis and treatment of juvenile myelomonocytic leukemia","volume":"58","author":"Sakashita","year":"2016","journal-title":"Pediatr Int"},{"issue":"6","key":"10.1016\/j.beha.2020.101195_bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2010.08525.x","article-title":"Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia","volume":"152","author":"Loh","year":"2011","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.beha.2020.101195_bib27","doi-asserted-by":"crossref","first-page":"28914","DOI":"10.18632\/oncotarget.8016","article-title":"Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group","volume":"7","author":"Bresolin","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.beha.2020.101195_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2010.08196.x","article-title":"Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations","volume":"150","author":"Sugimoto","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2020.101195_bib29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.beha.2020.101195_bib30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.beha.2020.101195_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib32","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng.641","article-title":"Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia","volume":"42","author":"Niemeyer","year":"2010","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib33","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2020.101195_bib34","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2009-06-226340","article-title":"Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia","volume":"115","author":"Muramatsu","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2020.101195_bib35","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"Caye","year":"2015","journal-title":"Nat Genet"},{"issue":"19","key":"10.1016\/j.beha.2020.101195_bib36","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib37","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2020.101195_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2020.101195_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib40","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2020.101195_bib41","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.beha.2020.101195_bib42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2020.101195_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajh.24637","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.beha.2020.101195_bib44","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101195_bib45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101195_bib46","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2020.101195_bib47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2020.101195_bib48","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3324\/haematol.2012.072538","article-title":"High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic\/myeloproliferative neoplasms","volume":"98","author":"Jeromin","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib49","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Broseus","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2020.101195_bib50","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.beha.2020.101195_bib51","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.leukres.2010.02.033","article-title":"Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations","volume":"34","author":"Szpurka","year":"2010","journal-title":"Leuk Res"},{"issue":"17","key":"10.1016\/j.beha.2020.101195_bib52","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2020.101195_bib53","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101195_bib54","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2020.101195_bib55","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy","volume":"28","author":"DiNardo","year":"2014","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.beha.2020.101195_bib56","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101195_bib57","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1038\/bcj.2015.113","article-title":"Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Canc J"},{"key":"10.1016\/j.beha.2020.101195_bib58","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Canc J"},{"issue":"12","key":"10.1016\/j.beha.2020.101195_bib59","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41408-017-0004-0","article-title":"ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS","volume":"7","author":"Sallman","year":"2017","journal-title":"Blood Canc J"},{"key":"10.1016\/j.beha.2020.101195_bib60","series-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients","author":"Coltro","year":"2019"},{"issue":"3","key":"10.1016\/j.beha.2020.101195_bib61","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1203\/PDR.0b013e3181961d2a","article-title":"Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia","volume":"65","author":"Yoshida","year":"2009","journal-title":"Pediatr Res"},{"issue":"4","key":"10.1016\/j.beha.2020.101195_bib62","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00277-011-1326-9","article-title":"Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia","volume":"91","author":"Park","year":"2012","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101195_bib63","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/MPH.0b013e3181e7571e","article-title":"Myeloproliferative disorder in Noonan syndrome","volume":"33","author":"Bastida","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"10.1016\/j.beha.2020.101195_bib64","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2006-09-046649","article-title":"Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations","volume":"109","author":"Matsuda","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2020.101195_bib65","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2020.101195_bib66","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/leu.2016.216","article-title":"Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis","volume":"30","author":"Patnaik","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.beha.2020.101195_bib67","doi-asserted-by":"crossref","first-page":"43295","DOI":"10.18632\/oncotarget.17177","article-title":"Prognostic role of TET2 deficiency in myelodysplastic syndromes: a meta-analysis","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.beha.2020.101195_bib68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2020.101195_bib69","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2010-01-263087","article-title":"Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis","volume":"116","author":"Huls","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101195_bib70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2020.101195_bib71","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.beha.2020.101195_bib72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.beha.2020.101195_bib73","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2020.101195_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ejh.12223","article-title":"Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic\/myeloproliferative neoplasms","volume":"92","author":"Fu","year":"2014","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2020.101195_bib75","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101195_bib76","first-page":"162","article-title":"Promising results of a phase 1\/2 clinical trial of ruxolitinib in patients with chronic myelomonocytic leukemia","volume":"130","author":"Padron","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101195_bib77","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2020.101195_bib78","first-page":"JCO1900895","article-title":"Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","author":"Dao","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101195_bib79","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2019-130501","article-title":"Preliminary results from the phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS)","volume":"134","author":"Richard-Carpentier","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101195_bib80","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1182\/blood-2019-122380","article-title":"Outcomes of IDH-mutated advanced phase ph-negative myeloproliferative neoplasms treated with IDH inhibitors","volume":"134","author":"Cahill","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101195_bib81","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2019-123854","article-title":"Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML)","volume":"134","author":"Steensma","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101195_bib82","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2019-131055","article-title":"Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML)","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2020.101195_bib83","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2020.101195_bib84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2017.11.006","article-title":"A phase 1\/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia","volume":"64","author":"Navada","year":"2018","journal-title":"Leuk Res"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:57Z","timestamp":1761498357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1521692620300566"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101195","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular genetics of MDS\/MPN overlap syndromes","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101195"}}